# Pfizer: Phase 3 study closed enrollment, 896 enrolled (Ulcerative Colitis)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Pfizer |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis |
| NCT ID | NCT03950232 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Ulcerative Colitis |
| Intervention types | drug |
| Target enrollment | 896 |
| Site countries | United States, Argentina, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark |
| Posted | 2019-05-15 |
| Planned start | 2019-09-05 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-23 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 896 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03950232). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.